# WindMIL Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/windmil-therapeutics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.windmiltherapeutics.com
- Total disclosed funding: $43M
- Latest round: Series B (Jun 1, 2018)
- Investors on record: 7

## About

Based in the US, WindMIL Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative cell therapies to address unmet medical needs in cancer treatment.Founded in 2015, WindMIL Therapeutics, Inc. operates out of Baltimore, US, focusing on cell therapy solutions for cancer patients. The company has completed three funding rounds, with the latest being a Venture Debt round raising USD 2.335 mn on January 26, 2021. The company was founded by Kimberly Noonan, who previously led initiatives in the biotech field, and is currently led by CEO Don Hayden.WindMIL Therapeutics specializes in advanced cell therapy products aimed at providing innovative solutions for cancer treatment. Their core offerings are designed to enhance patient outcomes through targeted therapies, addressing specific challenges within the oncology market. Their products cater to a diverse customer base, including hospitals and healthcare providers in North America, Europe, and select Asian markets, focusing on improving treatment efficacy and patient care.The company implements a revenue model built on direct sales of its innovative therapies, as well as establishing strategic partnerships with healthcare organizations. Revenue primarily comes from contracts with hospitals and clinics, which are engaged through service agreements for ongoing access to their therapies. Pricing structures are tiered to accommodate various healthcare providers, ensuring accessibility for both smaller practices and larger hospital systems. WindMIL Therapeutics leverages its proprietary therapies as a key driver of revenue, establishing a foundation for sustained financial growth.WindMIL Therapeutics plans to advance its product portfolio with new therapies aimed at enhancing treatment options for cancer patients. The company is focusing on expanding its presence in the European market by 2023, targeting collaborations with leading healthcare institutions. The recent funding of USD 2.335 mn from the Venture Debt round will be utilized to support clinical trials and research initiatives, driving the development of new therapies and facilitating market entry strategies.

## Funding rounds

- Series B, Jun 1, 2018, $33M — Domain Associates, Qiming Venture Partners, FoxKiser, LINEA Investment, Silver Rock Financial, Catalio Capital Management, Kinneret Advisory
- Series A, Mar 29, 2016, $10M — Domain Associates, FoxKiser, Silver Rock Financial

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B
- FoxKiser — Series A, Series B
- Silver Rock Financial — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- LINEA Investment (https://capitalatlas.ai/funds/linea-investment) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Kinneret Advisory — Series B